Insight Molecular Diagnostics Inc. Common Stock (IMDX) — Analysis Summary
Insight Molecular Diagnostics Inc. Common Stock (IMDX) has a market cap of $103.74M with year-over-year revenue growth of +115.6%. Net margin stands at -1238.5%. The stock trades at a P/E ratio of -2.1.
Key Takeaways
- Revenue changed +115.6% year-over-year
- Net margin of -1238.5%
- P/E ratio of -2.1
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, IMDX posted revenue growth of +115.6% and trades at a P/E of -2.1.
Insight Molecular Diagnostics Inc. Common Stock (IMDX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -513.2x — earnings do not cover interest payments
Operating margin at -3011.9% — severe operating losses
Net margin at -2955.6% — losses exceed revenue (possible one-time charges)
Revenue fell 58.8% vs the prior period.
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees
58
Headquarters
NASHVILLE, TN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.